Rivernorth Capital Management’s ZyVersa Therapeutics ZVSA Stock Holding History

Rivernorth Capital Management’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-786	Closed	-$2.75M	–	756
2022 Q3	$2.75M	Buy	+786	New	+$2.74M	0.12%	177

Other funds holding ZVSA

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return

Rivernorth Capital Management's ZVSA Position: Q4 2022 in Review

Rivernorth Capital Management sold out of ZyVersa Therapeutics (ZVSA) in Q4 2022, closing a stake of 786 shares — an estimated $2.75M sold.

Rivernorth Capital Management first reported a position in ZVSA in Q3 2022 and held it in 1 quarter. The position peaked at $2.75M in Q3 2022. 2 funds tracked by Wall St. Rank hold ZVSA as of Q4 2022.

Rivernorth Capital Management reported no remaining ZyVersa Therapeutics position as of Q4 2022 after selling out during the quarter.
Rivernorth Capital Management sold 786 ZyVersa Therapeutics shares in Q4 2022, an estimated $2.75M.
Rivernorth Capital Management first reported a position in ZyVersa Therapeutics in Q3 2022 and held it in 1 quarter.
Rivernorth Capital Management's ZyVersa Therapeutics position peaked at $2.75M in Q3 2022.
2 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2022.

Based on Rivernorth Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.